alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 29 studies with an author at Kyoto University (JP) (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of these 29 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Estimating the Effect of Hospital Admission on Health Care Outcomes and Spending Among Persons With Dementia : A Quasi-experimental Study

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Annals of internal medicine 2026-06-09

Among Medicare beneficiaries with dementia who visited an ED, there was no evidence that hospital admission was associated with mortality rates. 5 key findings →

Design: cohort Participants: 872,085 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral small vessel disease genomics and its implications across the lifespan

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Nature communications 2020-12-08

White matter hyperintensities (WMH) are the most common brain-imaging feature of cerebral small vessel disease (SVD), hypertension being the main known risk factor. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Efficacy and Safety of Cilostazol in Mild Cognitive Impairment: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA network open 2023-12-01

The full analysis set included 159 patients (66 [41.5%] male; mean [SD] age, 75.6 [5.2] years) who received placebo or cilostazol at least once. 2 key findings →

Design: clinical trial Participants: 159 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Neurology 2021-09-16

These results from the largest longitudinal cohort registry of patients with CAA-ri support the transient and potentially relapsing inflammatory nature of the clinical-radiologic acute manifestations of the disease and the effectiveness of slow oral tapering off after IV corticosteroid pulse therapy in preventing recurrences. 3 key findings →

Design: longitudinal study Participants: 113 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes: A Target Trial Emulation

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Annals of Internal Medicine 2025-07-22

Among older adults with diabetes, no clear evidence was found that the incidence of dementia differed overall between patients using GLP-1RAs versus DPP4is. 4 key findings →

Design: cohort Participants: 7,254 Evidence: early

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Science (New York, N.Y.) 2024-08-23

Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer's disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Nature 2018-01-31

This study demonstrated the measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry to predict individual brain amyloid-β status as determined by amyloid-β-PET imaging. 4 key findings →

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Nature genetics 2000-07-01

Autosomal recessive juvenile parkinsonism (AR-JP), one of the most common familial forms of Parkinson disease, is characterized by selective dopaminergic neural cell death and the absence of the Lewy body, a cytoplasmic inclusion body consisting of aggregates of abnormally accumulated proteins. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

TREM2 is a receptor for non-glycosylated mycolic acids of mycobacteria that limits anti-mycobacterial macrophage activation

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nature communications 2021-04-16

Mycobacterial cell-wall glycolipids elicit an anti-mycobacterial immune response via FcRγ-associated C-type lectin receptors, including Mincle, and caspase-recruitment domain family member 9 (CARD9). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Oxidative damage is the earliest event in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neuropathology and experimental neurology 2001-08-01

Recently, we demonstrated a significant increase of an oxidized nucleoside derived from RNA, 8-hydroxyguanosine (8OHG), and an oxidized amino acid, nitrotyrosine in vulnerable neurons of patients with Alzheimer disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Nature Aging 2025-11-20

Cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia with no specific treatment, of which molecular mechanisms remain poorly understood. 2 key findings →

Participants: 40,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement

✓ Peer-reviewed alzhub usefulness score 48 out of 100. American journal of human genetics 2011-06-16

Autosomal-dominant spinocerebellar ataxias (SCAs) are a heterogeneous group of neurodegenerative disorders. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Multidomain interventions for preventing cognitive decline in older adults with type 2 diabetes and mild cognitive impairment: Secondary analysis of the J-MINT

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Aging Research and Lifestyle 2025-01-01

Multidomain interventions may benefit younger older adults or those with overly strict or lenient HbA1c control; however, these findings need confirmation in future studies. 3 key findings →

Participants: 531 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Differential effects of a multidomain intervention on cognitive decline in older adults with type 2 diabetes according to white matter hyperintensity status: A secondary analysis of the J‐ MIND ‐Diabetes

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Diabetes Obesity and Metabolism 2025-07-14

Among 90 participants included in the analyses, 34 had moderate to severe WMH. 5 key findings →

Participants: 154 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Importance of a comprehensive geriatric assessment in prediction of complications following thoracic surgery in elderly patients

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Chest 2005-03-01

The prevalence of comorbidities and functional impairment among elderly patients may enhance the risk of operation-related complications, but the importance of these conditions in elderly patients undergoing thoracic surgery remains unclear. 4 key findings →

Participants: 120 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Psychiatry and clinical neurosciences 2001-02-01

We studied the prevalence of dementing disorders in a rural town of Japan (Amino-cho), using a door-to-door two-phase design. 2 key findings →

Participants: 170 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of biological chemistry 2012-05-04

Accumulating evidence suggests that some dietary patterns, specifically high fat diet (HFD), increase the risk of developing sporadic Alzheimer disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuropathology and experimental neurology 1998-11-01

Recent studies have shown that deficient functioning of glutamate transporters (GTs) in Alzheimer disease (AD) might lead to neurodegeneration via excitotoxicity; however, the characteristics of cell death and pathways involved are not yet clear. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Evaluation of chewing ability and its relationship with activities of daily living, depression, cognitive status and food intake in the community-dwelling elderly

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Geriatrics & gerontology international 2012-12-21

The aim of this study was to assess chewing ability using color-changeable chewing gum and to show the association between chewing ability and geriatric functions, as well as dietary status in the community-dwelling elderly. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed